Mucopolysaccharidosis I (MPS I) represents a rare genetic lysosomal storage condition resulting from deficient alpha-L-iduronidase enzyme activity, causing widespread glycosaminoglycan accumulation across organ systems. The Mucopolysaccharidosis I Drugs Market has undergone significant transformation driven by revolutionary advances in enzyme supplementation therapies, stem cell...